The SEPP1 concentrations and GPX activity levels of subjects in the present trial, whose average baseline plasma selenium concentration was approximately 108 mcg/L—much lower than that of subjects in SELECT, but higher than that of many subjects in NPC—were not affected statistically significantly, or substantially, by supplementation. This evidence concerns the gene SELENOP and nasopharyngeal carcinoma.